Eloxx Pharmaceuticals (ELOX) Gets a Hold Rating from H.C. Wainwright
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Hold rating on Eloxx Pharmaceuticals (ELOX), with a price target of $3.00. The company’s shares closed last Tuesday at $3.16.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 16.7% and a 50.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eloxx Pharmaceuticals with a $4.50 average price target.
See today’s analyst top recommended stocks >>
Based on Eloxx Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.13 million. In comparison, last year the company had a GAAP net loss of $11.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded on December 19, 2017 and is headquartered in Waltham, MA.
Read More on ELOX: